

[1］Levine OS，O’Brien KL，Knoll M.Pneumococcal vaccination in developing countries［J］.Lancet，2006，367：1880-1882. 

[2］杜娟，杨启文，徐英春，等.社区呼吸道感染肺炎链球菌对头孢妥仑的耐药机制研究［J］.中国感染与化疗杂志，2012，12(3)：199-205. 

[3］易锦发，孟要武，林惠巧.社区获得性肺炎病原学研究及临床对策［J］.南方医科大学学报,2009,29(1):90-91. 

[4］陈雪莹,张卫星.社区获得性肺炎患者联合检测肺炎支原体和衣原体的临床研究［J］.实用临床医药杂志,2014,18(12):20-23. 

[5］王辉.社区获得性肺炎病原体学及致病菌耐药性变迁［J］.中国实用内科杂志，2009，29(8)：772-775. 

[6］王咏红，佟月娟，俞桑洁，杨永弘.儿童肺炎链球菌对β-内酰胺类、大环内酯类和氟喹诺酮类抗菌药物敏感性研究［J］.首都医科大学学报，2005，26(5)：517-520. 

[7］李耘，刘健，薛峰，等.卫生部全国细菌耐药监测网(Mohnarin)2007-2008年报告［J］.中国临床药理学杂志，2011，27(5)：323-334. 

[8］王辉，孙宏莉，陈民钧，等.2005-2006年我国九家教学医院分离的常见呼吸道病原菌的耐药监测研究［J］.中华检验医学杂志，2007，30(11)：1242-1247. 

[9］丁晶晶，苗立云，李燕,等.江苏省南京地区肺炎链球菌对β-内酰胺类抗生素耐药及传播机制［J］.实用临床医药杂志,2014,18(9):22-26. 

[10］南月敏，张庆山，王荣琦.硬化并发肺部感染抗生素经验治疗［J］.中国实用内科杂志，2013，33（9）：684-686. 

[11］各国社区获得性肺炎指南对非典型病原体的重视情况［J］.中国实用内科杂志，2009，29（10）:953-954. 

[12］Xiao YH，Wang J，Li Y.Bacterial resistance surveillance in China：a report from Mohnarin 2004-2005［J］.Eur J Clin Microbiol Infect Dis，2008，27(8)：697-708. 

[13］de la Campa AG，Ardanuy C，Balsalobre L，et al.Changes in fluoroquinolone-resistant Streptococcus pneumoniae after 7-valent conjugate vaccination，Spain［J］.Emerg Infect Dis，2009，15(6)：905-911. 

[14］胡付品，朱德妹，汪复，等.2011年中国CHINET细菌耐药性监测［J］.中国感染与化疗杂志，2012，12(5)：321-329. 

[15］Johnson AP，Speller DC，Warner M，et al.In-vitro activity of levofloxacin (l-ofloxacin)，ofloxacin and ciprofloxacin against clinical isolates of Streptococcus pneumoniae obtained in England and Wales［J］.J Antimicrob Chemother，1996，38(5)：907-908. 

[16］Hooper DC.Fluoroquinolone resistance among gram-positive cocci［J］.Lancet Infect Dis，2002，2：530-538. 

[17］龙泉鑫，何颖，谢建平.喹诺酮类药物作用的生理和遗传的分子机制［J］.药学学报，2012，47(8)：969-977. 

[18］Laponogov I，Sohi MK，Veselkov DA，et al.Structural insight into the quinolone-DNA cleavage complex of type ⅡA topoisomerases［J］.Nat Struct Mol Biol，2009，16(6)：667-669. 

[19］Morais Cabral JH，Jackson AP，Smith CV，et al.Crystal structure of the breakage-reunion domain of DNA gyrase［J］.Nature，1997，388(6645)：903-906. 

[20］李家泰，Allan J Weinstein，杨敏.中国细菌耐药监测研究［J］.中华医学杂志，2001，81(1)：8-16. 

[21］赵铁梅，刘又宁.肺炎链球菌192株对新喹诺酮类体外耐药性测定［J］.中国抗感染化疗杂志，2003，3(6)：325-327. 

[22］刘又宁，陈民钧，赵铁梅，等.中国城市成人社区获得性肺炎665例病原学多中心调查［J］.中华结核和呼吸杂志，2006，29(1)：3-8. 

[23］肖永红，王进，赵彩云，等.2006-2007年Mohnarin细菌耐药监测［J］.中华医院感染学杂志，2008，18(8)：1051-1056. 

[24］汪健，李华，胡晓彦，等.社区获得性肺炎病原菌构成及耐药分析［J］.实验与检验医学，2011，29(3)：227-229. 

[25］骆骥才，杨青，俞云松，等.2010年中国CHINET呼吸道病原菌分布及耐药性分析［J］.中国感染与化疗杂志，2012，12(5)：340-347. 

[26］杨青，俞云松，孙自镛，等.2011年中国CHINET呼吸道病原菌分布和耐药性监测［J］.中国感染与化疗杂志，2013，13(5)：357-364. 

[27］闵小春，罗少锋，伍婷婷，等.肺炎链球菌的耐药性监测［J］.中华医院感染学杂志，2014，24(13)：3149-3151. 

[28］张璟，孙自镛，马越，等.152株肺炎链球菌的耐药性及血清分型研究［J］.中华医院感染学杂志，2007，17(4)：468-471. 

[29］肖素坤，赵春江，刘春林，王辉.我国成人和儿童中分离的肺炎链球菌的耐药性与血清型研究［J］.中华结核和呼吸杂志，2010，33(8)：601-607. 

[30］王启，张菲菲，赵春江.2010-2011年中国肺炎链球菌耐药性和血清型研究［J］.中华结核和呼吸杂志，2013，36(2)：106-112. 

[31］Lismond A，Carbonnelle S，Verhaegen J，et al.Antimicrobial susceptibility of Streptococcus pneumoniae isolates from vaccinated and non-vaccinated patients with a clinically confirmed diagnosis of community-acquired pneumonia in Belgium［J］.Int J Antimicrob Agents，2012，39(3)：208-216. 

[32］Anagaw B，Gezachew M，Biadgelgene F，et al.Antimicrobial susceptibility patterns of Streptococcus pneumoniae over 6 years at Gondar University Hospital，Northwest Ethiopia［J］.Asian Pac J Trop Biomed，2013，3(7)：536-541. 

[33］Kang CI，Song JH，Kim SH，et al.Association of levofloxacin resistance with mortality in adult patients with invasive pneumococcal diseases：a post hoc analysis of a prospective cohort［J］.Infection，2013，41(1)：151-157. 

[34］Karlowsky JA，Adam HJ，Desjardins M，et al.Changes in fluoroquinolone resistance over 5 years (CANWARD 2007-11) in bacterial pathogens isolated in Canadian hospitals［J］.J Antimicrob Chemother，2013，68 Suppl 1：i39-46. 

[35］Lee S，Kim SH，Park M，et al.High prevalence of multiresistance in levofloxacin- nonsusceptible Streptococcus pneumoniae isolates in Korea［J］.Diagn Microbiol Infect Dis，2013，76(2)：227-231. 

[36］Jones RN，Sader HS，Mendes RE，et al.Update on antimicrobial susceptibility trends among Streptococcus pneumoniae in the United States：report of ceftaroline activity from the SENTRY Antimicrobial Surveillance Program (1998-2011)［J］.Diagn Microbiol Infect Dis，2013，75(1)：107-109. 

[37］Maraki S，Papadakis IS.Antimicrobial resistance trends among community-acquired respiratory tract pathogens in Greece，2009-2012［J］.Scientific World Journal，2014，2014：941564. 

[38］Ozawa D，Yano H，Hidaka H，et al.Twelve-year survey (2001-2012) of the antimicrobial susceptibility of Streptococcus pneumoniae isolates from otorhinolaryngology clinics in Miyagi Prefecture，Japan［J］.J Infect Chemother，2014，pii：S1341-321X(14)00255-4. 

[39］Gant CM，Rosingh AW，Lopez-Hontangas JL，et al.Serotype distribution and antimicrobial resistance of invasive pneumococcal disease strains in the Comunidad Valenciana，Spain，during the winter of 2009-2010：low PCV7 coverage and high levofloxacin resistance［J］.Antimicrob Agents Chemother，2012，56(9)：4988-4989. 

[40］Lupien A，Billal DS，Fani F，et al.Genomic characterization of ciprofloxacin resistance in a laboratory-derived mutant and a clinical isolate of Streptococcus pneumoniae［J］.Antimicrob Agents Chemother，2013，57(10)：4911-4919. 

[41］Janoir C，Zeller V，Kitzis MD，et al.High-level ?uoroquinolone resistance in Streptococcus pneumoniae requires mutations in parC and gyrA［J］.Antimicrob Agents Chemother，1996，40：2760-2764. 

[42］Stewart BA，Johnson AP，Woodford N.Relationship between mutations in parC and gyrA of clinical isolates of Streptococcus pneumoniae and resistance to cipro?oxacin and grepa?oxacin［J］.J Med Microbiol，1999，48：1103-1106. 

[43］Bowker KE，Garvey MI，Noel AR，et al.Comparative antibacterial effects of moxifloxacin and levofloxacin on Streptococcus pneumoniae strains with defined mechanisms of resistance：impact of bacterial inoculum［J］.J Antimicrob Chemother，2013，doi：10.1093/jac/dks537. 

[44］Pletz MW，Fugit RV，McGee L，et al.Fluoroquinolone-resistant Streptococcus pneumoniae［J］.Emerg Infect Dis，2006，12(9)：1462-1463. 

[45］佘婷婷，徐元宏.肺炎链球菌耐药性及其耐药机制研究［J］.国外医药抗生素分册，2011，32(1)：32-37. 

[46］Jones ME，Sahm DF，Martin N，et al.Prevalence of gyrA，gyrB，parC，and parE mutations in clinical isolates of Streptococcus pneumoniae with decreased susceptibilities to different fluoroquinolones and originating from worldwide surveillance studies during the 1997-1998 respiratory season［J］.Antimicrob Agents Chemother，2000，44：462-466. 

[47］Guo Q，Zhuo C，Xu Y，et al.Genetic diversity of fluoroquinolone-nonsusceptible Streptococcus pneumoniae clinical isolates and the first identification of serotype 20B in China［J］.Eur J Clin Microbiol Infect Dis，2014，33(3)：465-470. 

[48］Ip M，Chau SS，Chi F，et al.Fluoroquinolone resistance in atypical pneumococci and oral streptococci：evidence of horizontal gene transfer of fluoroquinolone resistance determinants from Streptococcus pneumoniae［J］.Antimicrob Agents Chemother，2007，51(8)：2690-2700. 

[49］Park HS，Jung SJ，Choi DR，et al.Antimicrobial activity of DW286 against Streptococcus pneumoniae［J］.Int J Antimicrob Agents，2010，36(3)：230-233. 

[50］Rozen DE，McGee L，Levin BR，et al.Fitness costs of fluoroquinolone resistance in Streptococcus pneumoniae［J］.Antimicrob Agents Chemother，2007，51(2)：412-416. 

[51］de la Campa AG，Balsalobre L，Ardanuy C.Fluoroquinolone resistance in penicillin-resistant Streptococcus pneumoniae clones，Spain［J］.Emerg Infect Dis，2004，10(10)：1751-1759. 

[52］Zhang G，Tian W，Wang C，et al.Identification of a novel resistance mutation in parE that confers high-level resistance to moxifloxacin in Streptococcus pneumoniae［J］.J Antimicrob Chemother，2012，67(11)：2773-2774. 

[53］Hooper DC.Mechanisms of fluoroquinolone resistance［J］.Drug Resist Updat，1999，2(1)：38-55. 

[54］Almahmoud I，Kay E，Schneider D，et al.Mutational paths towards increased fluoroquinolone resistance in Legionella pneumophila［J］.J Antimicrob Chemother，2009，64(2)：284-293. 

[55］Sutera V，Maxime L，Burmeister WP，et al.Evolution toward high-level fluoroquinolone resistance in Francisella species［J］.J Antimicrob Chemother，2013，doi：10.1093/jac/dkt321. 

[56］Toprak E，Veres A，Michel JB，et al.Evolutionary paths to antibiotic resistance under dynamically sustained drug selection［J］.Nat Genet，2012，44(1)：101-105. 

[57］Weinreich DM，Delaney NF，Depristo MA，et al.Darwinian evolution can follow only very few mutational paths to fitter proteins［J］.Science，2006，312：111-114. 

[58］Zeller V，Janoir C，Kitzis MD，et al.Active Ef?ux as a Mechanism of Resistance to Cipro?oxacin in Streptococcus pneumoniae［J］.Antimicrob Agents Chemother，1997，41(9)：1973-1978. 

[59］Brenwald NP，Gill MJ，Wise R.Prevalence of a putative efflux mechanism among fluoroquinolone-resistant clinical isolates of Streptococcus pneumoniae［J］.Antimicrob Agents Chemother，1998，42(8)：2032-2035. 

[60］Gill MJ，Brenwald NP，Wise R.Identification of an efflux pump gene，pmrA，associated with fluoroquinolone resistance in Streptococcus pneumoniae［J］.Antimicrob Agents Chemother，1999，43(1)：187-189. 

[61］Marrer E，Schad K，Satoh AT，et al.Involvement of the putative ATP-dependent efflux proteins PatA and PatB in fluoroquinolone resistance of a multidrug-resistant mutant of Streptococcus pneumoniae［J］.Antimicrob Agents Chemother，2006，50(2)：685-693. 

[62］El Garch F，Lismond A，Piddock LJ，et al.Fluoroquinolones induce the expression of patA and patB，which encode ABC efflux pumps in Streptococcus pneumoniae［J］.J Antimicrob Chemother，2010，65(10)：2076-2082. 

[63］苏纪平.莫西沙星在治疗急性上呼吸道感染中的地位［J］.中国医学文摘耳鼻咽喉科学，2009，24(6)：304-305. 

[64］Burkhardt O，Welte T.10 years’ experience with the pneumococcal quinolone moxifloxacin［J］.Expert Rev Anti Infect Ther，2009，7(6)：645-668. 

[65］蒲纯.莫西沙星与左氧氟沙星联合甲硝唑治疗伴有吸入性危险因素社区获得性肺炎的临床研究解读［J］.中国实用内科杂志，2014，34(9)：929-930. 

[66］金建敏，孙永昌.呼吸喹诺酮治疗社区获得性肺炎的再认识与再评价［J］.中国实用内科杂志，2014，34(8)：829-830. 